La Jolla jumps on positive Phase III cardiovascular data

Californian biotech firm La Jolla Pharmaceutical (Nasdaq: LJPC) has published in The New England Journal of Medicine data from a Phase III results into LJPC-501 (angiotensin II) as a treatment for the heart condition vasodilatory shock.

Rinaldo Bellomo, director of Intensive Care Research at Austin Health, said: “In the study, angiotensin II was shown to raise blood pressure with no increase in overall adverse events as compared to placebo.”

“The effect of angiotensin II resulted in reduced use of other vasopressors. If approved, angiotensin II, in combination with other vasopressors, may allow clinicians to leverage all three major physiologic systems that regulate blood pressure.”